270 related articles for article (PubMed ID: 32996065)
1. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Sodhi JK; Liu S; Benet LZ
Pharm Res; 2020 Sep; 37(10):208. PubMed ID: 32996065
[TBL] [Abstract][Full Text] [Related]
2. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Kou W; Sodhi JK; Wu X; Benet LZ
Pharm Res; 2021 May; 38(5):795-801. PubMed ID: 33847849
[TBL] [Abstract][Full Text] [Related]
3. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
5. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
7. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.
Margelidon-Cozzolino V; Hodin S; Jacqueroux E; Delézay O; Bertoletti L; Delavenne X
J Pharmacol Exp Ther; 2018 Jun; 365(3):519-525. PubMed ID: 29572341
[TBL] [Abstract][Full Text] [Related]
9. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
[TBL] [Abstract][Full Text] [Related]
10. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
12. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
[TBL] [Abstract][Full Text] [Related]
14. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
15. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
[TBL] [Abstract][Full Text] [Related]
16. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Wang C; Liu KX
Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
[TBL] [Abstract][Full Text] [Related]
17. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
18. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake T
Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
